Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01247142 |
Recruitment Status
:
Completed
First Posted
: November 24, 2010
Last Update Posted
: July 8, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Invasive Pulmonary Aspergillosis |
Study Type : | Observational |
Actual Enrollment : | 24 participants |
Time Perspective: | Prospective |
Study Start Date : | January 2011 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |

Group/Cohort |
---|
Invasive pulmonary aspergillosis (IPA)
Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
|
Controls
Patients without signs of infection.
|
- The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC) [ Time Frame: 15 months ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- hospitalisation in the hematology or intensive care department
- age > 16 years
- informed consent
- proven or probable IPA (EORTC/ MSG criteria)
- galactomannan positivity in BAL or serum
Exclusion Criteria:
- age < 16 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01247142
Belgium | |
UZ Leuven | |
Leuven, Belgium, 3000 |
Responsible Party: | Edith Vermeulen, PhD fellow, Universitaire Ziekenhuizen Leuven |
ClinicalTrials.gov Identifier: | NCT01247142 History of Changes |
Other Study ID Numbers: |
S52756 |
First Posted: | November 24, 2010 Key Record Dates |
Last Update Posted: | July 8, 2014 |
Last Verified: | July 2014 |
Keywords provided by Edith Vermeulen, Universitaire Ziekenhuizen Leuven:
invasive pulmonary aspergillosis exhaled breath condensate |
Additional relevant MeSH terms:
Aspergillosis Pulmonary Aspergillosis Invasive Pulmonary Aspergillosis Mycoses Hyalohyphomycosis Dermatomycoses |
Lung Diseases, Fungal Skin Diseases, Infectious Skin Diseases Lung Diseases Respiratory Tract Diseases Invasive Fungal Infections |